China’s Breakthrough Obesity Drug Mazdutide Achieves Record Weight Loss in Global Study
A landmark Phase 3 clinical study of mazdutide, the world’s first dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, has been published in The New England Journal of Medicine (NEJM), signaling a pivotal advancement in the fight against obesity. The trial, known as GLORY-1, demonstrates the remarkable efficacy and safety of mazdutide in Chinese adults with … Read more
Sharing is Caring